Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation-Reply

JAMA. 2022 Apr 5;327(13):1290. doi: 10.1001/jama.2022.1428.
No abstract available

Publication types

  • Comment

MeSH terms

  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use
  • Atrial Fibrillation* / complications
  • Atrial Fibrillation* / drug therapy
  • Dabigatran / adverse effects
  • Fibrinolytic Agents* / adverse effects
  • Fibrinolytic Agents* / therapeutic use
  • Hemorrhage / chemically induced
  • Humans
  • Ischemia / chemically induced
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use
  • Pyridones / adverse effects
  • Pyridones / therapeutic use
  • Rivaroxaban* / adverse effects
  • Rivaroxaban* / therapeutic use
  • Stroke / etiology
  • Stroke / prevention & control

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Pyrazoles
  • Pyridones
  • apixaban
  • Rivaroxaban
  • Dabigatran